Biotyscience Inc
E-mail biotyscience@gmail.com
info@biotyscience.com
Tel 400-669-8850
Cat No | ADMD-083 |
Conjugate | |
Type | 重组蛋白 |
Source | HEK293 |
Tag | His |
Size | 1mg |
Application | Immunology |
Format | Liquid |
Purity | >90 %, SDS-PAGE |
Concentration | Please refer to the vial lable for the specific concentration. |
Buffer | Supplied in PBS |
Species | Human |
Storage | Store at -20 degree. Avoid repeated freeze/thaw cycles. |
Synonyms | T cell immunoreceptor with Ig and ITIM domains, TIGIT, VSIG9, VSTM3, WUCAM |
Purification | Protein A/G |
Note | For research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. |
MolecularWeight | 13.9 kDa |
Description | |
Background | T cell immunoreceptor with Ig and ITIM domains(TIGIT), also named as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane do-maincontaining protein 3 (VSTM3) and Washington University cell adhesion molecule (WUCAM), is a co-inhibitory molecule belonging to the immunoglobulin superfamily that was first discovered in 2009. It consists of an extracellular immunoglobulin variable (IgV) domain, a type I transmembrane domain and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoglobulin tail tyrosine (ITT)-like motif. TIGIT is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently widely being investigated in both pre-clinical and clinical studies. In multiple cancers TIGIT is expressed on tumor-infiltrating cytotoxic T cells, helper T cells, regulatory T cells and NK cells, and its main ligand CD155 is expressed on tumor-infiltrating myeloid cells and upregulated on cancer cells, which contributes to local suppression of immune-surveillance. |